Biolinerx Stock Price, News & Analysis

Welcome to our dedicated page for Biolinerx news (Ticker: BLRX), a resource for investors and traders seeking the latest updates and insights on Biolinerx stock.

BioLineRx Ltd. (BLRX) generates frequent news flow as a biopharmaceutical company focused on oncology and rare diseases. Its updates cover the performance of its approved product APHEXDA (motixafortide), progress in clinical trials, and developments in its partnerships and joint ventures.

News about BioLineRx often highlights APHEXDA’s commercial performance in stem cell mobilization for autologous transplantation in multiple myeloma, including royalty revenues from Ayrmid Ltd. and Gloria Biosciences. Investors and observers can follow how APHEXDA sales contribute to BioLineRx’s reported revenues and how the company manages its operating expenses and cash runway.

A significant portion of BLRX news relates to clinical development milestones. This includes data from the CheMo4METPANC Phase 2b trial of motixafortide in metastatic pancreatic cancer, such as pilot‑phase outcomes and biomarker analyses, as well as updates on Phase 1 studies of motixafortide for CD34+ hematopoietic stem cell mobilization in gene therapies for sickle cell disease. Company announcements also describe conference presentations at major oncology meetings.

Another key news theme is the GLIX1 joint venture with Hemispherian AS. Releases describe the structure of the joint venture, IND clearance for a Phase 1/2a glioblastoma study, Orphan Drug Designation, and intellectual property milestones, including a U.S. Patent and Trademark Office Notice of Allowance for a patent covering GLIX1 in cancers where cytidine deaminase is not over‑expressed.

Visitors to this BLRX news page can review press releases on quarterly and annual financial results, corporate updates, shareholder meeting outcomes, and regulatory filings referenced in Form 6‑K reports. For anyone tracking BioLineRx’s pipeline evolution, partnerships and financial position, this consolidated news feed offers a structured view of the company’s ongoing activities.